A Phase 1, Open-Label, Multi-Site Study to Assess Psychological Effects of MDMA-Assisted Psychotherapy When Administered to Healthy Volunteers (MT2)

The new MAPS-sponsored MT2 study is a Phase 1, open-label, multi-site research study designed to assess the safety and psychological effects of manualized MDMA-assisted therapy in healthy normal volunteers (HNVs) using validated measures to collect data on changes in self-compassion, professional quality of life, and professional burnout following MDMA administration in healthy volunteer therapists undergoing training to treat people suffering from PTSD with MDMA-assisted therapy. MT2 is a vital part of the MDMA Therapy Training Program. Many therapists who have participated in MT1 consider the experience to have been an invaluable part of their training that improved their ability to provide this treatment to PTSD patients in our clinical trials. While not providing pivotal efficacy data, the study will serve to increase understanding of MDMA’s clinical effects in a therapeutic setting as well as enhance therapist training, and may therefore prove relevant in the treatment of PTSD patients.

Study Status: In development

Study Timeline
Study Protocol (March 14, 2019)
Study Protocol (March 20, 2019)
Study Protocol (August 27, 2019)
Study Protocol (December 27, 2019)